XML 260 R216.htm IDEA: XBRL DOCUMENT
v3.22.4

Segment information - Schedule of Reconciliation Between Business Operating Income for the Segments and Income Before Tax and Investments Accounted for Using the Equity Method (Details) € in Millions, $ in Millions |  | 1 Months Ended | 12 Months Ended
--- | --- | --- | ---
May 29, 2020 EUR (€) shares | Jun. 30, 2022 EUR (€) | Jun. 30, 2022 USD ($) | Dec. 31, 2022 EUR (€) | Dec. 31, 2022 USD ($) | Dec. 31, 2021 EUR (€) shares | Dec. 31, 2020 EUR (€)
Disclosure of operating segments [line items] |  |  |  |  |  |  |  |  |
Share of profit/(loss) from investments accounted for using the equity method |  |  |  | € 68 |  | € 39 |  | € 359 |
Net income attributable to non-controlling interests |  |  |  | 113 |  | 56 | [1] | 36 | [1],[2]
Fair value remeasurement of contingent consideration |  |  |  | (27) |  | 4 |  | (124) | [3]
Restructuring costs and similar items |  |  |  | (1,336) |  | (820) |  | (1,089) | [3]
Other gains and losses, and litigation |  |  |  | (370) |  | (5) |  | 136 | [3]
Operating income |  |  |  | 10,656 |  | 8,126 |  | 14,113 | [3]
Financial expenses |  |  |  | (440) |  | (368) |  | (388) | [3]
Financial income |  |  |  | 206 |  | 40 |  | 53 | [3]
Income before tax and investments accounted for using the equity method |  |  |  | 10,422 |  | 7,798 |  | 13,778 | [3]
Other intangible assets |  |  |  |  |  |  |  |  |
Disclosure of operating segments [line items] |  |  |  |  |  |  |  |  |
Impairment of other intangible assets, net of reversals (excluding software) |  |  |  | (454) |  | € 192 |  | 330 |
Other intangible assets | SAR444245 |  |  |  |  |  |  |  |  |
Disclosure of operating segments [line items] |  |  |  |  |  |  |  |  |
Impairment of other intangible assets, net of reversals (excluding software) |  |  |  | 1,586 |  |  |  |  |
Eloctate |  |  |  |  |  |  |  |  |
Disclosure of operating segments [line items] |  |  |  |  |  |  |  |  |
Reversal amount |  |  |  | 2,154 |  |  |  |  |
Regeneron Pharmaceuticals, INC | Immuno-oncology collaboration agreement |  |  |  |  |  |  |  |  |
Disclosure of operating segments [line items] |  |  |  |  |  |  |  |  |
Upfront payments for projects under collaboration agreements | $ |  |  |  |  | $ 900 |  |  |  |
Regular milestone payments for projects under collaboration agreements |  | € 96 | $ 100 |  | $ 100 |  |  |  |
Regeneron |  |  |  |  |  |  |  |  |
Disclosure of operating segments [line items] |  |  |  |  |  |  |  |  |
Share of profit/(loss) from investments accounted for using the equity method | € 343 |  |  |  |  |  |  | 343 |
Non-current financial assets, number of shares (in shares) | shares | 400,000 |  |  |  |  | 279,766 |  |  |
Regeneron | Public offering |  |  |  |  |  |  |  |  |
Disclosure of operating segments [line items] |  |  |  |  |  |  |  |  |
Sale of stock, number of shares issued in transaction (in shares) | shares | 13,000,000 |  |  |  |  |  |  |  |
Regeneron | Repurchase from the counterpart | Regeneron Pharmaceuticals, INC |  |  |  |  |  |  |  |  |
Disclosure of operating segments [line items] |  |  |  |  |  |  |  |  |
Shares agreement, sale of stock, number of shares issued in transaction (in shares) | shares | 9,800,000 |  |  |  |  |  |  |  |
Operating segments |  |  |  |  |  |  |  |  |
Disclosure of operating segments [line items] |  |  |  |  |  |  |  |  |
Business operating income |  |  |  | 13,040 |  | € 10,714 |  | 9,759 |
Material reconciling items |  |  |  |  |  |  |  |  |
Disclosure of operating segments [line items] |  |  |  |  |  |  |  |  |
Share of profit/(loss) from investments accounted for using the equity method |  |  |  | (88) |  | (39) |  | (16) |
Net income attributable to non-controlling interests |  |  |  | 33 |  | 56 |  | 38 |
Amortization and impairment of intangible assets (c) |  |  |  | (1,599) |  | (1,772) |  | (2,011) |
Fair value remeasurement of contingent consideration |  |  |  | 27 |  | (4) |  | 124 |
Expenses arising from the impact of acquisitions on inventories |  |  |  | (3) |  | (4) |  | (53) |
Restructuring costs and similar items |  |  |  | (1,336) |  | (820) |  | (1,089) |
Other gains and losses, and litigation |  |  |  | (370) |  | (5) |  | 136 |
Gain on divestment of Regeneron shares on May 29, 2020 |  |  |  | 0 |  | 0 |  | 7,225 |
Income from out-licensing |  |  |  | € 952 |  | € 0 |  | € 0 |
[1] | Includes the impacts of the IFRIC final agenda decisions of March 2021 on the costs of configuring or customising application software used in a Software as a Service (SaaS) arrangement and of April 2021 on the attribution of benefits to periods of service, as described in Note A.2.1. to the consolidated financial statements for the year ended December 31, 2021.
[2] | (j) Includes the impacts of the IFRIC final agenda decisions of March 2021 on the costs of configuring or customising application software used in a Software as a Service (SaaS) arrangement and of April 2021 on the attribution of benefits to periods of service, as described in Note A.2.1. to the consolidated financial statements for the year ended December 31, 2021.
[3] | Includes the impacts of the IFRIC final agenda decisions of March 2021 on the costs of configuring or customising application software used in a Software as a Service (SaaS) arrangement and of April 2021 on the attribution of benefits to periods of service, as described in Note A.2.1. to the consolidated financial statements for the year ended December 31, 2021.

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfOperatingSegmentsLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of expense relating to restructuring. Restructuring is a programme that is planned and controlled by management and materially changes either the scope of a business undertaken by an entity or the manner in which that business is conducted. Such programmes include: (a) the sale or termination of a line of business; (b) closure of business locations in a country or region or the relocation of activities from one country or region to another; (c) changes in management structure; and (d) fundamental reorganisations that have a material effect on the nature and focus of the entity's operations. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2021-01-01 -Paragraph 98 -Subparagraph b -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_98_b&doctype=Standard -URIDate 2021-03-24 + Details
Name: | ifrs-full_ExpenseOfRestructuringActivities
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of costs associated with financing activities of the entity. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2021-01-01 -Paragraph 82 -Subparagraph b -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_82_b&doctype=Standard -URIDate 2021-03-24 + Details
Name: | ifrs-full_FinanceCosts
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of income associated with interest and other financing activities of the entity. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2021-01-01 -Paragraph 85 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_85&doctype=Standard -URIDate 2021-03-24 + Details
Name: | ifrs-full_FinanceIncome
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The increase (decrease) in a contingent consideration asset (liability) relating to a business combination. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 3 -IssueDate 2021-01-01 -Paragraph B67 -Subparagraph b -Clause i -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B67_b_i&doctype=Appendix&subtype=B -URIDate 2021-03-24 + Details
Name: | ifrs-full_IncreaseDecreaseInContingentConsiderationAssetLiability
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2021-01-01 -Paragraph 12 -Subparagraph e -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_12_e&doctype=Standard -URIDate 2021-03-24 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2021-01-01 -Paragraph 81B -Subparagraph a -Clause i -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81B_a_i&doctype=Standard -URIDate 2021-03-24 + Details
Name: | ifrs-full_ProfitLossAttributableToNoncontrollingInterests
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The profit (loss) from operating activities of the entity. [Refer: Profit (loss)] + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Name IAS -Number 32 -IssueDate 2021-01-01 -Paragraph IE33 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=32&code=ifrs-tx-2021-en-r&anchor=para_IE33&doctype=Illustrative%20Examples -URIDate 2021-03-24 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2021-01-01 -Paragraph 85 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_85&doctype=Standard -URIDate 2021-03-24 + Details
Name: | ifrs-full_ProfitLossFromOperatingActivities
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The entity's share of the profit (loss) of associates and joint ventures accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Joint ventures [member]; Profit (loss)] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2021-01-01 -Paragraph 23 -Subparagraph g -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23_g&doctype=Standard -URIDate 2021-03-24 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2021-01-01 -Paragraph 28 -Subparagraph e -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_e&doctype=Standard -URIDate 2021-03-24 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Note Effective on first application of IFRS 9 -Name IFRS -Number 4 -IssueDate 2021-01-01 -Paragraph 39M -Subparagraph b -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2021-en-b&anchor=para_39M_b&doctype=Standard -URIDate 2021-03-24 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2021-01-01 -Paragraph 82 -Subparagraph c -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_82_c&doctype=Standard -URIDate 2021-03-24 + Details
Name: | ifrs-full_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethod
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amortization and impairment of intangible assets other than goodwill. + References No definition available. + Details
Name: | sny_AmortizationAndImpairmentOfIntangibleAssetsOtherThanGoodwill
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Business operating income. + References No definition available. + Details
Name: | sny_BusinessOperatingIncome
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Expenses arising from the impact of acquisitions on inventories. + References No definition available. + Details
Name: | sny_ExpenseArisingFromTheImpactOfAcquisitionsOnInventories
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Gain On Regeneron Investment Sold + References No definition available. + Details
Name: | sny_GainOnRegeneronInvestmentSold
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Impairment loss on intangible assets other than goodwill. + References No definition available. + Details
Name: | sny_ImpairmentLossOnIntangibleAssetsOtherThanGoodwill
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Impairment Loss Recognised In Profit Or Loss, Intangible Assets Other Than Goodwill, Reversal Amount + References No definition available. + Details
Name: | sny_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwillReversalAmount
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Income before tax and investments accounted for equity method investments. + References No definition available. + Details
Name: | sny_IncomeBeforeTaxAndInvestmentsAccountedForEquityMethodInvestments
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Income Resulting From Out-Licensing + References No definition available. + Details
Name: | sny_IncomeResultingFromOutLicensing
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Non-Current Financial Assets, Number Of Shares + References No definition available. + Details
Name: | sny_NonCurrentFinancialAssetsNumberOfShares
Namespace Prefix: | sny_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition The line item other gains and losses, and litigation includes the impact of material transactions of an unusual nature or amount. [note B.20.2.] + References No definition available. + Details
Name: | sny_OtherGainsLossesAndLitigation
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Regular Milestone Payments For Projects Under Collaboration Agreements + References No definition available. + Details
Name: | sny_RegularMilestonePaymentsForProjectsUnderCollaborationAgreements
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Sale Of Stock, Number Of Shares Issued In Transaction, Total + References No definition available. + Details
Name: | sny_SaleOfStockNumberOfSharesIssuedInTransactionTotal
Namespace Prefix: | sny_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Shares Agreement Sale Of Stock, Number Of Shares Issued In Transaction + References No definition available. + Details
Name: | sny_SharesAgreementSaleOfStockNumberOfSharesIssuedInTransaction
Namespace Prefix: | sny_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Upfront Payments For Projects Under Collaboration Agreements + References No definition available. + Details
Name: | sny_UpfrontPaymentsForProjectsUnderCollaborationAgreements
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=ifrs-full_OtherIntangibleAssetsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ProductsAndServicesAxis=sny_SAR444245Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=sny_EloctateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=sny_RegeneronPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sny_PrincipalAlliancesAxis=sny_ImmunoOncologyCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInAssociatesAxis=sny_RegeneronMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sny_SaleOfStockAxis=sny_PublicOfferingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sny_SaleOfStockAxis=sny_RepurchaseFromTheCounterpartMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SegmentConsolidationItemsAxis=ifrs-full_MaterialReconcilingItemsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |